SCHEMBL4322909

SCHEMBL4322909

CCOC(=O)CCc1nc2ccc(NC(C)=O)cn2c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PPID Q08752 1/20 0.40
MCHR1 Q99705 1/20 0.39
MAPT P10636 4/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 4/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4534424 0.81 LMNA (0.42) LMNAKMT2ACYP1A2MAPTALDH1A1
SCHEMBL4454170 0.81 SMN1; SMN2 (0.41) LMNATDP1MCHR1ALDH1A1KDM4E
SCHEMBL4311336 0.80 SMN1; SMN2 (0.45) LMNAKMT2AMEN1TDP1MCHR1
Hydrochloric Acid SCHEMBL4314109 0.80 LMNA (0.41) LMNAKMT2AMAPTALDH1A1KDM4E
SCHEMBL4327172 0.77 MAPT (0.43) LMNACYP1A2MAPTALDH1A1KDM4E
SCHEMBL4328691 0.77 MCHR1 (0.46) KMT2AMEN1MCHR1RAB9ANPC1
SCHEMBL4328686 0.77 MCHR1 (0.46) KMT2AMEN1MCHR1RAB9ANPC1
SCHEMBL4315927 0.77 LMNA (0.46) LMNAMCHR1MAPTPOLB
SCHEMBL4311352 0.76 KDM4E (0.43) KMT2AMEN1CYP1A2MAPTALDH1A1
SCHEMBL4317648 0.74 KDM4E (0.52) LMNAKMT2AMEN1CYP1A2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 US disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 US disclosed
EP-1748048-A1 IMIDAZOPYRIDINE COMPOUND BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 LMNA 3634/4885KMT2A 555/4885MEN1 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.